基于TSH的「达标时间」评估甲状腺功能减退症疾病控制
本研究利用2016-2022年单中心纵向临床数据,对2752例接受左甲状腺素(LT4)治疗且至少2年内有≥3次TSH检测的成人患者,采用对数转换TSH线性插值法估算达标时间(TIR)。结果显示中位TIR为86%,男性及黑人种族与TIR<75%相关,TIR与LT4剂量负相关,TAR与心血管事件关联接近显著。
要点
- 基于系列TSH的TIR可量化甲减慢性病控制水平
- 男性及黑人种族与TIR<75%独立相关
- LT4剂量与TIR呈负相关,TAR与心血管事件接近显著
核心结论
- 基于TSH的TIR可识别不同社会人口学群体间甲减疾病控制的差异及LT4剂量的影响。
研究设计与样本
- 单中心纵向临床数据研究(2016-2022年),纳入≥18岁、接受LT4治疗且至少2年内有≥3次独立TSH检测的患者,共2752例。
主要发现
- 研究入组期中位TIR为86%,中位随访3.8年。
- 男性和女性中LT4剂量与TIR均呈负相关(R=-0.23和-0.30;P均<.001)。
- 男性(OR 1.30;P<.001)和黑人种族(OR 1.37;P<.001)与TIR<75%相关。
- TAR与心血管事件的关联接近显著(每增加10% TAR,OR 1.03;P=.078)。
临床怎么用
- 可利用系列TSH估算TIR作为甲减慢性病控制的量化指标。
- 对男性和黑人患者需关注TIR<75%的风险,加强疾病控制评估。
- LT4剂量与TIR负相关,调整剂量时需综合评估疾病控制情况。
局限性
- 研究为单中心回顾性设计,结论外推需谨慎。
- TIR与心血管事件的关联未达统计学显著,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Time-in-range (TIR) using sequential TSH levels during levothyroxine (LT4) treatment could serve as a measure of chronic disease control in hypothyroidism. OBJECTIVES: Primary objectives: (1) develop a method of estimating TIR and (2) determine the impact of patient sociodemographic characteristics on TIR. Secondary objective: investigate the relationship between TIR and time to cardiovascular event. METHODS: The study was conducted using longitudinal clinical data (2016-2022) from a single academic institution. Study participants were ≥18 years old, LT4-treated, and had ≥3 unique TSH levels collected over a minimum of 2 years. For each patient, TIR, time-above-range (TAR) and time-below-range (TBR) were estimated using linear interpolation of log-transformed TSH levels. Fitted linear regression was used to evaluate the relationship between TIR/TAR/TBR and LT4 dose over the study period. Generalized estimating equations were used to model annualized TIR/TAR/TBR with sociodemographic and clinical covariates. Survival analysis was used to characterize the relationship between TIR and occurrence of cardiovascular events. RESULTS: A total of 2752 LT4-treated patients had a median TIR of 86% over the study enrollment period (median, 3.8 years). For both males and females, LT4 dose was negatively correlated with TIR (R = -0.23 and -0.30, respectively; P < .001 for both). Male sex and Black race were associated with TIR <75% (OR, 1.30; P < .001; OR, 1.37; P < .001). The association between TAR and cardiovascular events approached significance (OR, 1.03 per +10% TAR; P = .078). CONCLUSION: We used TIR estimation to identify differences in disease control between sociodemographic groups and the impact of LT4 dose. In future studies, we aim to better characterize the association between TIR and clinically meaningful outcomes.
引用
- Ettleson MD, Thomas N, Ramirez M, et al. Measuring Hypothyroidism Disease Control Using a TSH-based "Time-in-range". J Clin Endocrinol Metab. 2026. PMID: 40645612. doi:10.1210/clinem/dgaf393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。